{"nctId":"NCT00347932","briefTitle":"A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.","startDateStruct":{"date":"2006-06"},"conditions":["Acute Bacterial Conjunctivitis"],"count":957,"armGroups":[{"label":"ISV-403","type":"EXPERIMENTAL","interventionNames":["Drug: ISV-403"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"ISV-403","otherNames":["besifloxacin","Besivance","BOL-303224"]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have a diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in at least one eye.\n* Females of childbearing potential must utilized reliable contraceptive methods and have a negative pregnancy test.\n\nExclusion Criteria:\n\n* Pregnant or nursing females.\n* Known hypersensitivity to fluoroquinolones or to any of the study ingredients.\n* Use of any antibiotic within 72 hours of treatment.\n* Any disease or condition that could interfere with the safety and efficacy evaluations of the study medications.\n* Participation in an ophthalmic drug or device research study within 30 days prior to entry into the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Resolution of Baseline Bacterial Conjunctivitis","description":"The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"PRIMARY","title":"Microbial Eradication of Baseline Bacterial Infection","description":"Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Resolution of Baseline Bacterial Conjunctivitis","description":"The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbial Eradication of Baseline Bacterial Infection","description":"Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":442},"commonTop":[]}}}